Buffett’s Berkshire Hathaway has enough cash to theoretically buy every NFL team

Danish biotech Genmab announced on Monday that it will acquire cancer startup Merus in an all-cash deal worth about $8 billion.

Genmab is buying Merus for $97 per share, a roughly 40% premium over its closing price as of Friday. The deal was approved unanimously by both companies’ boards, Genmab said.

Merus’ experimental drug, petosemtamab, has shown encouraging results in mid-stage trials for metastatic head and neck cancer. The stock jumped more than 30% in premarket trading once the acquisition was announced.

Trendy nuclear power stock Oklo received a bullish review from Wall Street on Monday, with Barclays analysts starting coverage of the stock at “overweight” — basically a “buy” rating — alongside a price target of $146, a more than 30% premium to Friday’s close.

The underlying rationale is, of course, the AI data center boom, which is already boosting electricity demand — and raising utility bills — and is projected to do so for years to come.

Shares were up 5.8% premarket. Before today, the stock had soared more than 50% over the past month, but that includes a bit of a retrenchment over the past few sessions.

As a maker of small modular nuclear reactors (SMRs), Oklo and similar companies like Nuscale are seen as providing a possible technology that can bridge the growing gap between supply and projected demand.

But this is all very speculative, as these companies are not actually producing much of anything at the moment besides outstanding stock market returns.

Barclays analysts note that Oklo’s business currently encompasses a series of “non-binding agreements with various customers, such as data centers, military outposts, etc,” and Wall Street forecasts annual losses for the company through 2028.

Barclays analysts write of the shares:

Weed stocks are roaring out of the gate on Monday morning after President Donald Trump reposted a video from The Commonwealth Project detailing the benefits of hemp-derived CBD products for seniors as the “most important senior health initiative of the century.”

Canopy Growth, Tilray, SNDL Inc., and Cronos Group are all up between 10% and 20% as of 7 a.m. ET.

The clip says that hemp-derived CBD products offer relief from pain, inflammation, and cognitive decline faster than “dangerous and addictive” pharmaceuticals or tweaks to diet and lifestyle. This can “add years to your life,” per The Commonwealth Project, which bills itself as “working to prioritize the 65+ population by integrating medical cannabis into mainstream health care for seniors.”

The roughly three-minute-long video focuses on hemp-derived CBD products, but it also includes a clip from Fox News that claims annual cost savings to the US of nearly $64 billion per year if cannabis is fully integrated into the healthcare system.

Over the past couple of months, marijuana stocks have been powered by the potential for the Trump administration to reclassify marijuana as a less dangerous drug, which news reports and the president himself have suggested is under consideration.

The Commonwealth Project’s video hails the 2018 Farm Bill signed by Trump in his first term (which legalized hemp production at the federal level) as a “first step,” but also calls for Medicare coverage for CBD to “give millions of seniors the support they deserve.”